FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2907846619> ?p ?o ?g. }

• W2907846619 endingPage "432" @default.
• W2907846619 startingPage "432" @default.
• W2907846619 abstract "Abstract Effective targeting of the acute myeloid leukemia (AML) leukemia stem cell (LSC) population may allow for deep, durable remissions and curative potential. In older, newly diagnosed AML patients who are not candidates for induction, venetoclax + azacitidine (aza) targets specific metabolic vulnerabilities of LSCs, resulting in very promising clinical outcomes. In our single institution experience treating 45 previously untreated AML patients with venetoclax + aza both in the context of the multi-institutional study NCT02203773 (N=33) and with off-label use (N=12), 36/45 (80%) achieved a complete remission (CR) or CR with incomplete count recovery (CRi). In the relapsed/refractory (R/R) setting, the efficacy of venetoclax + aza has been reported to be significantly worse. In our single-institution off-label experience (N=7), only 1/7 (14%) R/R patients had a CR/CRi (p=0.005 compared to the untreated group). R/R and untreated patients had similar baseline characteristics, although more R/R patients had an antecedent hematological disorder (Table 1). Multivariate analysis showed cytogenetic risk and R/R disease as the sole predictors of response to venetoclax + aza (Table 2). In light of existing data regarding biological changes that occur in LSCs after treatment and subsequent relapse, we aimed to determine whether laboratory analysis of LSCs from patients treated with venetoclax + aza would show differential sensitivity to this therapy in the up-front vs R/R setting that could help to explain the different clinical activity. We have previously shown that LSCs from untreated patients are uniquely reliant on oxidative phosphorylation (OXPHOS), and that venetoclax + aza targets LSCs by decreasing OXPHOS. Therefore, we tested the hypothesis that inferior responses of R/R patients to venetoclax + aza are due to changes in OXPHOS regulation in relapsed LSCs. LSCs were defined as cells bearing relatively low levels of reactive oxygen species (ROS-low), an effective means of enriching primary human LSCs. We found that in contrast with untreated patients, venetoclax + aza does not decrease viability or OXPHOS in LSCs from R/R patients (Fig1). Furthermore, R/R LSCs had altered fatty acid metabolism that contributed to these OXPHOS differences, with increased flux of fatty acids into the TCA cycle (Fig 2). In addition, R/R samples compensated for the metabolic perturbations that occurred upon exposure to venetoclax + aza through upregulation of fatty acid uptake and metabolism into the TCA cycle (Fig 3). Fatty acid metabolism is controlled by multiple genes and pathways. Integral to its activity is the gene Carnitine Palmitolytransferase 1 (CPT1), due to its pivotal role in the beta-oxidation of long chain fatty acids. Investigation of the Cancer Genome Atlas AML dataset reveals higher expression of CPT1 leads to significantly worse overall survival, suggesting increased fatty acid metabolism may drive a more resistant LSC population in R/R AML patients. We also found elevated baseline levels of CPT1 in patients who progressed on venetoclax + aza compared to those that had long term remissions (not shown). Therefore we utilized the CPT1 inhibitor etomoxir to block fatty acid metabolism. We found addition of etomoxir to cultures of R/R LSCs rescued the ability of venetoclax + aza to decrease OXPHOS and re-sensitized R/R LSCs to venetoclax + aza (Fig 4). To prove that this novel regimen targets functionally-defined R/R LSCs we performed ex vivo treatment followed by xenotransplantation of R/R patient specimens, which showed that upon etomoxir addition, engraftment potential is significantly decreased over venetoclax + aza alone (not shown). Therefore we propose a novel mechanism for the increased resistance of R/R AML patients to venetoclax + aza involving altered energy metabolism. We find increased fatty acid metabolism in R/R patient specimens, and targeting this pathway using the CPT1 inhibitor etomoxir leads to sensitization to venetoclax + aza and rescued targeting of OXPHOS, allowing for LSC eradication. Disclosures Pollyea: Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Argenx: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Research Funding; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Consultancy; Celyad: Consultancy, Membership on an entity's Board of Directors or advisory committees; Curis: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees." @default.
• W2907846619 created "2019-01-11" @default.
• W2907846619 creator A5001285080 @default.
• W2907846619 creator A5004742310 @default.
• W2907846619 creator A5012012199 @default.
• W2907846619 creator A5016147813 @default.
• W2907846619 creator A5028354132 @default.
• W2907846619 creator A5032549755 @default.
• W2907846619 creator A5038867429 @default.
• W2907846619 creator A5041615072 @default.
• W2907846619 creator A5043793391 @default.
• W2907846619 creator A5043809217 @default.
• W2907846619 creator A5047917797 @default.
• W2907846619 creator A5087902006 @default.
• W2907846619 creator A5088085788 @default.
• W2907846619 date "2018-11-29" @default.
• W2907846619 modified "2023-10-02" @default.
• W2907846619 title "Relapsed Acute Myeloid Leukemia Is Less Sensitive to Venetoclax + Azacitidine Due to Leukemia Stem Cell Resistance Driven By Fatty Acid Metabolism and Can be Overcome By Pharmacologic Inhibition of CPT1" @default.
• W2907846619 doi "https://doi.org/10.1182/blood-2018-99-111507" @default.
• W2907846619 hasPublicationYear "2018" @default.
• W2907846619 type Work @default.
• W2907846619 sameAs 2907846619 @default.
• W2907846619 citedByCount "2" @default.
• W2907846619 countsByYear W29078466192022 @default.
• W2907846619 countsByYear W29078466192023 @default.
• W2907846619 crossrefType "journal-article" @default.
• W2907846619 hasAuthorship W2907846619A5001285080 @default.
• W2907846619 hasAuthorship W2907846619A5004742310 @default.
• W2907846619 hasAuthorship W2907846619A5012012199 @default.
• W2907846619 hasAuthorship W2907846619A5016147813 @default.
• W2907846619 hasAuthorship W2907846619A5028354132 @default.
• W2907846619 hasAuthorship W2907846619A5032549755 @default.
• W2907846619 hasAuthorship W2907846619A5038867429 @default.
• W2907846619 hasAuthorship W2907846619A5041615072 @default.
• W2907846619 hasAuthorship W2907846619A5043793391 @default.
• W2907846619 hasAuthorship W2907846619A5043809217 @default.
• W2907846619 hasAuthorship W2907846619A5047917797 @default.
• W2907846619 hasAuthorship W2907846619A5087902006 @default.
• W2907846619 hasAuthorship W2907846619A5088085788 @default.
• W2907846619 hasBestOaLocation W29078466191 @default.
• W2907846619 hasConcept C104317684 @default.
• W2907846619 hasConcept C126322002 @default.
• W2907846619 hasConcept C143998085 @default.
• W2907846619 hasConcept C150194340 @default.
• W2907846619 hasConcept C151730666 @default.
• W2907846619 hasConcept C190727270 @default.
• W2907846619 hasConcept C203014093 @default.
• W2907846619 hasConcept C2776239401 @default.
• W2907846619 hasConcept C2777938653 @default.
• W2907846619 hasConcept C2778461978 @default.
• W2907846619 hasConcept C2778729363 @default.
• W2907846619 hasConcept C2779282312 @default.
• W2907846619 hasConcept C2779343474 @default.
• W2907846619 hasConcept C2779675984 @default.
• W2907846619 hasConcept C2908647359 @default.
• W2907846619 hasConcept C54355233 @default.
• W2907846619 hasConcept C71924100 @default.
• W2907846619 hasConcept C86803240 @default.
• W2907846619 hasConcept C90924648 @default.
• W2907846619 hasConcept C99454951 @default.
• W2907846619 hasConceptScore W2907846619C104317684 @default.
• W2907846619 hasConceptScore W2907846619C126322002 @default.
• W2907846619 hasConceptScore W2907846619C143998085 @default.
• W2907846619 hasConceptScore W2907846619C150194340 @default.
• W2907846619 hasConceptScore W2907846619C151730666 @default.
• W2907846619 hasConceptScore W2907846619C190727270 @default.
• W2907846619 hasConceptScore W2907846619C203014093 @default.
• W2907846619 hasConceptScore W2907846619C2776239401 @default.
• W2907846619 hasConceptScore W2907846619C2777938653 @default.
• W2907846619 hasConceptScore W2907846619C2778461978 @default.
• W2907846619 hasConceptScore W2907846619C2778729363 @default.
• W2907846619 hasConceptScore W2907846619C2779282312 @default.
• W2907846619 hasConceptScore W2907846619C2779343474 @default.
• W2907846619 hasConceptScore W2907846619C2779675984 @default.
• W2907846619 hasConceptScore W2907846619C2908647359 @default.
• W2907846619 hasConceptScore W2907846619C54355233 @default.
• W2907846619 hasConceptScore W2907846619C71924100 @default.
• W2907846619 hasConceptScore W2907846619C86803240 @default.
• W2907846619 hasConceptScore W2907846619C90924648 @default.
• W2907846619 hasConceptScore W2907846619C99454951 @default.
• W2907846619 hasIssue "Supplement 1" @default.
• W2907846619 hasLocation W29078466191 @default.
• W2907846619 hasOpenAccess W2907846619 @default.
• W2907846619 hasPrimaryLocation W29078466191 @default.
• W2907846619 hasRelatedWork W2889423049 @default.
• W2907846619 hasRelatedWork W2899472109 @default.
• W2907846619 hasRelatedWork W3048827006 @default.
• W2907846619 hasRelatedWork W4220904329 @default.
• W2907846619 hasRelatedWork W4220981828 @default.
• W2907846619 hasRelatedWork W4283514695 @default.
• W2907846619 hasRelatedWork W4295350611 @default.
• W2907846619 hasRelatedWork W4296533015 @default.
• W2907846619 hasRelatedWork W4312094400 @default.
• W2907846619 hasRelatedWork W4386277967 @default.
• W2907846619 hasVolume "132" @default.
• W2907846619 isParatext "false" @default.
• W2907846619 isRetracted "false" @default.
• W2907846619 magId "2907846619" @default.

• next